Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINFOL-04 maintenance study of rinatabart sesutecan plus standard of care versus standard of care in recurrent platinum-sensitive ovarian cancer
2025-522167-15-00Phase 3Authorised
- Sponsor
- Genmab
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Rinatabart sesutecan plus standard of care with Standard of care (2 arms). Primary endpoint: Progression-free survival. Planned start Sep 2026; status: authorised.
02
Drugs
rinatabart sesutecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2025-522167-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522167-15-00.